



Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: ARG5**

Last Trade: 1.18

Trade Time: 4:00 PM ET  
Mar 21, 2018

Change: -0.02  (-1.667%)

Day Range 1.15 - 1.21

52-Week Range 1.15 - 17.40


Volume 286,535

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Feb 15, 2018

[Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy](#)

Feb 5, 2018

[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)

Jan 18, 2018

[Argos Announces One-for-Twenty Reverse Stock Split](#)

Jan 8, 2018

[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)

Nov 28, 2017

[Argos Provides Financial Update](#)

## Financials [\[ View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Jul 6, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)